Vascular Dementia Conferences | Neurology Conferences | Dementia Conferences | Neuroscience | Meetings | Events | USA | Europe | UK | Middle East | Asia Pacific

Theme: Integrating Recent Discoveries and Interpreting Vascular Dementia Research for Better Health

Vascular Dementia Congress 2018

scientific Program

Renowned Speakers

Adrian GaitÃ¡n FariÃ±as
IFEN institute for EEG Neurofeedback Gaitan Clinics
Spain

Albert Karimov
Infomed-Neuro
Russia

Anatoly Uzdensky
Southern Federal University
Russia

Hemanth Rao
The Neurological Institute
USA

Ayman Tourbah
The University Hospital of Rheims
France

James Gratwicke
The National Hospital for Neurology and Neurosurgery
UK

Joanna B. Strosznajder
Polish Academy of Sciences
Poland

Jyri Kussela
NeuroVitalia and Ataman Science
Spain

Nathalie Compagnone
ICDD-sas
France

Peter Poortvliet
University of Queensland
Australia

Safa Shehab
UAE University
UAE

Sepi Shokouhi
Vanderbilt University Institute of Imaging Science
USA

Shin-Han Tsai
Taipei Medical University Shuang Ho Hospital,
China

Steven Benvenisti
Partner at Davis, Saperstein & Salomon Personal Injury Law Firm NJ & NY
USA

Thomas F. Feiner
Director Institute for EEG-Neurofeedback
Germany

Trevor Archer
Professor University of Gothenburg
Sweden

Wolfram Kersten
Mind-up GmbH & CO.KG â€“ Bamberg
Germany

Chethan P. V. Rao
Program Director Baylor College of Medicine
USA

Davide Moretti
Consultant Neurologist National Institute of Research and Cure for Mental disorders and Dementia
Italy

Dhavendra Kumar
Consultant in Clinical Genetics University Hospital of Wales
UK

Fabio Grizzi
Senior Scientist Laboratory of Molecular Gastroenterology of the Humanitas Clinical and Research Center
Italy

Jennifer DeFeo
hair, Chicago School of Prof.Psychology
USA

Daqing
Head of Anaesthesia Research Imperial College London,
UK

Kuldip Sidhu
CEO & Founding Director Cell Therapeutics Pty Ltd
Australia

Kurt Jellinger
Prof, Inst. of Clinical Neurobiology
Austria

Lucia M. Vaina
Co-Dir, Massachusetts Gen. Hosp
USA

Martina Bebin
Professor of Neurology and Pediatrics UAB Epilepsy Center
USA

M. M. Khan

USA

O. Nuri Ozgirgin
Proffessor Bayindir Hospital
Turkey

Proffessor Bayindir Hospital
Consultant Queen Elizabeth Hospital
Hong Kong

Yawu Liu
Yawu Liu
Finland

Zameel Cader
Consultant Neurologist Nuffield Department of Clinical Neurosciences
UK

Aliaksandr Haretski
The Body Regeneration Center of EAFM
Poland

Alice Ming Lin Chong
City University of Hong Kong
China

Amir Tamiz
National Institute of Health, USA
USA

Ann Marie Gillie
Canadian Advocate for Epilepsy
Canada

Ara Bazyan
nstitute of Higher Nervous Activity and Neurophysiology of RAS
Russia

Vascular Dementia Congress 2018

Conference series llc LTD organizes conferences all around the world in 2017; here it is our pleasure to invite you to Neuroscience conference entitled 11th International Conference on Vascular Dementia during July 23-25, 2018, at Moscow, Russia.

Vascular Dementia 2018 that has CME credits has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Committee

Attendance at this meeting will enable you to:

Be part of a rich scientific programme incorporating the latest developments in preclinical neurodegenerative diseases like Dementia and Alzheimer's Diseases
Understand the shift towards prevention and early diagnosis of neurodegenerative disease as the future of research in the field
Join key opinion leaders in discussing regulatory and ethical implications of this research in clinical practice.
Network with speakers and other leading experts across disciplines.

Vascular dementia, also known as multi-infarct dementia (MID) and vascular cognitive impairment (VCI), is dementia caused by problems in the supply of blood to the brain, typically a series of minor strokes, leading to worsening cognitive decline that occurs step by step.

The term refers to a syndrome consisting of a complex interaction of cerebrovascular disease and risk factors that lead to changes in the brain structures due to strokes and lesions, and resulting changes in cognition. The temporal relationship between a stroke and cognitive deficits is needed to make the diagnosis.

Sessions/Tracks

Track 1 Dementia

Dementia is a general term for a decline in mental ability severe enough to interfere with daily life. Memory loss is an example. Alzheimer's is the most common type of dementia.

10th International Conference on Vascular Dementia February 22-23, 2018 Paris, France; 8th Global Experts Meeting on Advances in Neurology and Neuropsychiatry, August 27-28, 2018 Tokyo, Japan; 11th International Conference on Vascular Dementia, July 23-25, 2018 Moscow, Russia; 25th World Congress on Neurology & Neuroscience, June 18-19, 2018 Dublin, Ireland; 7th International Conference on Brain and Neurological Disorders, April 10-12, 2018 Amsterdam, Netherlands; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 4th Global Experts Meeting on Parkinson’s & Movement Disorders, May 14-15, 2018 Singapore; 8th International Conference on Addictive Disorders and Alcoholism, May 17-18, 2018 Singapore; 24th International Conference on Neuroscience and Neurochemistry, May 21-22, 2018 BIRMINGHAM, UK; 11th International Conference on Alzheimers Disease & Dementia, May 24-25, 2018,Vienna, Austria; 10th World Congress on Alzheimers Disease & Dementia, May 30-31, 2018 Osaka, Japan

Track 2 Semantic dementia

Semantic dementia (SD) is a progressive neurodegenerative disorder characterized by loss of semantic memory in both the verbal and non-verbal domains. However, the most common presenting symptoms are in the verbal domain (with loss of word meaning).

10th International Conference on Vascular Dementia, February 22-23, 2018 Paris, France; 8th Global Experts Meeting on Advances in Neurology and Neuropsychiatry, August 27-28, 2018 Tokyo, Japan; 11th International Conference on Vascular Dementia, July 23-25, 2018 Moscow, Russia; 25th World Congress on Neurology & Neuroscience, June 18-19, 2018 Dublin, Ireland; 7th International Conference on Brain and Neurological Disorders, April 10-12, 2018 Amsterdam, Netherlands; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 4th Global Experts Meeting on Parkinson’s & Movement Disorders, May 14-15, 2018 Singapore; 8th International Conference on Addictive Disorders and Alcoholism, May 17-18, 2018 Singapore; 24th International Conference on Neuroscience and Neurochemistry, May 21-22, 2018 BIRMINGHAM, UK; 11th International Conference on Alzheimers Disease & Dementia, May 24-25, 2018,Vienna, Austria; 10th World Congress on Alzheimers Disease & Dementia, May 30-31, 2018 Osaka, Japan

Track 3: Frontotemporal dementia

Frontotemporal dementia (frontotemporal lobar degeneration) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain — the areas generally associated with personality, behavior and language.

Track 4 Mild Dementia

Mild cognitive impairment (MCI) causes a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills. A person with MCI is at an increased risk of developing Alzheimer's or another dementia.

Track 5 Severe Dementia

Severe Dementia is caused by damage to brain cells. This damage interferes with the ability of brain cells to communicate with each other. When brain cells cannot communicate normally, thinking, behavior and feelings can be affected.

A range of tests and diagnostic procedures is needed to diagnose dementia, but there are several that are fairly commonly used to diagnose dementia. These tests for dementia are mainly tests of mental abilities, blood tests and brain scans. Tests can help the doctor learn whether dementia is caused by a treatable condition. Even for those dementias that cannot be reversed, knowing the type of dementia a person has can help the doctor prescribe medicines or other treatments that may improve mood and behavior and help the family.

Track 6 Dementia Care

Progressive dementia, which is dementia that gets worse with time, is the most common type. Five stages of progressive dementia have been outlined. They are part of the Clinical Dementia Rating (CDR), which professionals use to evaluate the progression of symptoms in patients with dementia. The five stages describe a patient’s ability to perform in six different areas of cognition and functioning: orientation, memory, judgment, home and hobbies, personal care, and community. The stages include early dementia, Moderate dementia, Advanced dementia, Test of dementia stages, Advances in research of dementia stages.

Track 7 Lewy Body Dementia

Alzheimer's disease and other types of dementia can be a challenging journey, not only for the person diagnosed but also for their family members and loved ones. Caring for someone with Alzheimer's or dementia can seem overwhelming at times, but the more information and support you have, the better you can navigate the demanding road ahead and determine the long-term care options that are best suited to you and your loved one. There are some Alzheimer’s care preparations that are best done sooner rather than later. It may be hard to consider these questions at first, as it means thinking about a time when your loved one is already well down the road of his or her Alzheimer’s journey.

Track 8 Vascular Dementia

Vascular Dementia is the protection, promotion, and optimization of health and abilities, prevention of illness and injury, facilitation of healing, alleviation of suffering through the diagnosis and treatment of human response, and advocacy in the care of individuals, families, groups, communities, and populations.

Track 9 Advances in Dementia Test

The mainstay of management of vascular dementia is the prevention of new strokes. This includes administering antiplatelet drugs and controlling major vascular risk factors. Neuroprotective drugs such as nimodipine, propentofylline, and posatirelin are currently under study and may be useful for vascular dementia. Omentum in the treatment of vascular dementia. The sub tracks includes Cholinisterase inhibitors, Impact of treatment with N-Acetylcysteine, Oral redox polymer therapeutics, Snoezellen and Multi sensory stimulation, Effect of thioctic and enantiomers, Role of phospholipids, Effects of brain afobazole.

Track 10 Dementia Stages

National Plan to Address Alzheimer’s Disease, a national effort to expand research in Alzheimer’s and related dementias prevention and treatment and to move the most promising drugs from discovery into clinical trials.

The Plan aims to prevent and effectively treat Alzheimer’s and related dementias by 2025. Its foundation is the 2011 National Alzheimer’s Project Act (NAPA), which was developed to create and maintain a national strategy to overcome the disease.

Conference series llc LTD organizes conference series all around the world in 2017; here it is our pleasure to invite you to Neuroscience conference entitled 11th International Conference onVascular Dementia during July 23-25, 2018, at Moscow, Russia

Vascular Dementia 2018 that has CME credits has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Committee

In vascular dementia, changes in thinking skills sometimes occur suddenly following strokes that block major brain blood vessels. Vascular brain changes often coexist with changes linked to other types of dementia, including Alzheimer's disease and dementia with Lewy bodies. Vascular dementia symptoms may be most obvious when they happen soon after a major stroke includes confusion, disorientation, trouble speaking or understanding speech and vision loss.

Vascular dementia is the second-most-common type of dementia in the United States and Europe in the elderly, however it is the most common form in some parts of Asia. The incidence of the illness is 1.5% in Western countries and just about 2.2% in Japan. It accounts for 50% of all dementias in Japan, 20% to 40% in Europe and 15% in Latin America. The prevalence of dementia is 9 times higher in patients who have had a stroke than in controls. 25% of stroke patients develop new-onset dementia within 1 year of their stroke. The relative risk of incident dementia is 5.5% within 4 years of suffering a stroke.

The overall multi infarct dementia market is segmented into North America, Asia Pacific, Europe, Latin America and MEA. As of 2014, North America held largest market share in terms of revenue owing to the increasing incidences of multi infarct dementia coupled with increasing geriatric population base. European market displayed similar traits and followed North American multi infarct dementia market. Asia Pacific is expected to grow at a high pace due to increasing awareness about prevention of brain strokes in this region. Japan owing to increased geriatric base represents approximately more than 50% of the dementia cases in Asia Pacific. The developed nations such as Japan, Canada, France, Germany and U.S. are anticipated to witness favourable growth over the forecast period.

Various companies in the multi infarct dementia market are adopting several economical strategies such as collaborations, expansions and acquisitions to keep a strong position and gain advantage in the market. Some major companies in the market include Forest Laboratories, Inc., Janssen Pharmaceuticals, Inc., Novartis Pharmaceutical Corporation, Pfizer, Inc. and Eisai, Inc.

Why to attend ?

Vascular Dementia Conference is a unique forum to bring together worldwide distinguished academics in the field of Neuroscience and Neurology, Nutrition, Researchers, Public health professionals, Scientists, Academic scientists, Industry researchers, Scholars to exchange about state of the Research and Development.

Aim of this conference is stimulate new ideas for treatment that will be beneficial across the spectrum of Vascular Dementia. A Unique Opportunity for Advertisers and Sponsors at this International event.

Target Audience

Business delegates, Industrial Leaders, Vascular Dementia Researchers, Neurologist, Neuroscientist,

Vascular Dementia 2018 welcomes attendees, exhibitors and presenters all over the world to our conference venue Russia. We will be delighted to invite you all attending for “11th International Conference on Vascular Dementia” that would be held during July 23-25, 2018 Moscow, Russia, with the theme: Integrating Recent Discoveries and Interpreting Vascular Dementia Research for Better Health.

The organizing committee is planning for an exciting conference program which provides valuable information that includes plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants all over the world. We invite your presence joining us at Vascular dementia 2018, where you will gain meaningful experience with scholars from around the world. All members of Vascular Dementia 2018 look forward meeting you in Russia soon.

This conference provide support, increases knowledge, gain knowledge, assist learning, also allow families and future careers to seek the most applicable services for their loved one and to develop the best possible home environment to support recovery from the conditions of complex and devastating diseases.

Vascular dementia in other words called as multi-infarct dementia (MID). The name vascular cognitive impairment (VCI), is kind of dementia caused by problems in the supply of blood to the brain, with series of minor strokes. Vascular dementia is thought to be irreversible and it is caused by a number of small strokes or sometimes a large stroke preceded or followed by other smaller strokes. Vascular dementia is the second-most-common form of dementia after Alzheimer's disease (AD) in older adults. This refers to a group of symptoms that are caused by various mechanisms that results in vascular lesions in brain. The Early stages of detection, accurate diagnosis are very important, as vascular dementia is very less partially preventable.

Importance and Scope:

The treatment for global market in evaluation of syndromes for vascular dementia, with the movement disorders values are of range 10.5 billion in 2011 that reach $11.1 billion in 2012. Total market value that is expected to reach $16.7 billion in 2017 with raise at a five-year compound annual growth rate (CAGR) of 8.5%.

From every corner of the world, someone develops dementia every 3 seconds. This was an estimated value at 46.8 million people worldwide living with dementia in 2015 and the number is expected to be close to 50 million people in 2017. This number may double every 20 years, reaching 75 million in 2030 and 131.5 million in 2050. Mostly it is observed too be increased in developing countries. For now, 58% of people with dementia are living in low and middle income countries, may be, by 2050 this can rise to 68%.

Worldwide results of current meta-analysis reveal 44 million people (worldwide) suffered with dementia during 2010 and expected to double every 20 years, to the number 65.7 million in 2030 and 115.4 million in 2050. In 2010, 58 per cent of all people with low or middle incomes were with dementia lived in countries. This proportion anticipated in increase to 63 per cent in 2030 and 71 per cent in 2050.The values are expected to double by 2030 and triple by 2050 to 115 million.

The survey reveals in United States, an estimate of many as five million people age 65 and older suffer from Alzheimer’s disease.

Dementia is most widely considered to be the second common cause of Alzheimer's disease, accounting for 10 % of cases. Many experts believe vascular dementia remains less diagnosed for Alzheimer's disease, even the disease is common.

Alzheimer's Research UK at present funds 150 research projects across UK and focusing on developing stages which has been committed nearly £40million to dementia research.

Their research focus is on improvement of the quality of life already living with Alzheimer’s disease and also other forms of dementia.

Vascular Dementia 2018 provides a good platform where everyone will be sure having a meaningful experience with scholars, experts across the globe. The members of Vascular Dementia 2018 wishes meeting you in Moscow, Russia.

Why Moscow??

Moscow the capital of Russia is the most populous city with population of 12.2 million residents and 17.1 million in urban area. Moscow has the status of a Russian federal city.

Moscow is the largest city in the European continent and it has major political, economic, cultural, and scientific centre of Russia and Eastern Europe. Moscow has been ranked as ninth most expensive city in the world and has one of the world's largest urban economies. It has been ranked as an alpha global city and also the fastest growing tourist destinations in the world.

Moscow is northernmost, coldest megacity on Earth. It is based on the Moskva River in the Central Federal District of European Russia, making Europe as the most populated inland city. Moscow is better known for its architecture, especially the historic buildings like Saint Basil's Cathedral which has brightly colored domes. It has about 40 percent covered by greenery in the territory, which is one of the greenest capitals and also the major cities in Europe as well as the world. It has the largest forest in an urban area surrounding within its borders. It has vast expansion by 2012. Moscow has served the capital with progression of states, from the medieval Grand Duchy of Moscow followed by the subsequent Tsardom of Russia to the Russian Empire to the Soviet Union and the contemporary Russian Federation.

Conference Highlights

· Dementia

· Semantic Dementia

· Front temporal Dementia

· Mild Dementia

· Severe Dementia

· Dementia Care

· Lewy Body Dementia

· Vascular Dementia

· Advances in Dementia Test

· Dementia Stages

Funding Projects

· Alzheimer’s Research UK

· Alzheimer's Association

· Alzheimer's Disease Education and Referral Center (ADEAR)

· National Institute on Aging

· Alzheimer's Foundation of America

· Alzheimer’s Drug Discovery Foundation

· Association for Frontotemporal Degeneration (AFTD)

· BrightFocus Foundation

· John Douglas French Alzheimer's Foundation

· Lewy Body Dementia Association

· National Institute of Mental Health (NIMH)

· National Organization for Rare Disorders (NORD)

· BRACE - Alzheimer's Research

· Alzheimer's Society

· Alzheimer's Society of Canada

Target Audience

· Directors

· Head of Department

· Professors

· Industrial

· Neurologist

· Neuroscientist

· Neurosurgeons

· Psychiatrist

· Nutritional Scientists

· Students from Academia in the research of Neurology, Nutrition

Top universities 500 globally working in the field of Vascular Dementia.

· Harvard University

· University College London

· University of California--San Francisco

· Stanford University

· Massachusetts Institute of Technology

· Johns Hopkins University

· University of California--Los Angeles

· University of California--San Diego

· Columbia University

· University of Oxford

· University of Cambridge

· Yale University

· University of Pennsylvania

· University of Toronto

· Washington University in St. Louis

· New York University

· McGill University

· King's College London

· Karolinska Institute

· California Institute of Technology

Top Hospitals Associated with Vascular Dementia Research in World.

· John Hopkins Medicine

· Massachusetts General Hospital

· Siloam Hospitals

· Mayo Clinic

· The Mount Sinai Hospital

· Jefferson Hospital for Neuroscience

· Neurology Florida Hospital

· UNM Neurology Centre

· Tampa General Hospital

· Huntington Hospital

· EI Camino Hospital

There are above 500 Companies Associated with Vascular Dementia Research in World.

· Forest Laboratories

· Janssen Pharmaceuticals

· Novartis Pharmaceutical Corporation

· Pfizer

· Eisai

· Actinogen Limited

· Alector LLC

· AlzProtect SAS

· TauRx Therapeutics Ltd

· Pacific Northwest Biotechnology

· Tautatis Incorporated

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	July 23-25, 2018
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1	Day 2
Poster Opportunity Closed	Click Here to View